{"nctId":"NCT02806713","briefTitle":"The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)","startDateStruct":{"date":"2016-02"},"conditions":["Dysfunctional Voiding","Postoperative Pain"],"count":92,"armGroups":[{"label":"no phenazopyridine","type":"PLACEBO_COMPARATOR","interventionNames":["Other: no Phenazopyridine"]},{"label":"phenazopyridine","type":"EXPERIMENTAL","interventionNames":["Drug: Phenazopyridine"]}],"interventions":[{"name":"Phenazopyridine","otherNames":["Pyridium"]},{"name":"no Phenazopyridine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Any female subjects scheduled to undergo Mid-Urethral Sling (MUS) through the UMass urogynecology service for incontinence.\n\nExclusion Criteria:\n\n1. Planned concurrent prolapse or other procedure besides cystoscopy\n2. Using intermittent self catheterization preoperatively\n3. Undergoing spinal anesthesia for the procedure\n4. Known allergy to phenazopyridine (AKA Pyridium)\n5. Renal insufficiency\n6. Any condition or situation that in the attending physician's opinion would contra-indicate the use of phenazopyridine\n7. Subjects not competent to give consent\n8. Prisoners\n9. Non-English speaking patients\n10. Age \\<18\n11. Pregnant patients\n12. Contraindications to the use of IV methylene blue including\n\n    1. Patients with known hypersensitivity reactions\n    2. Severe renal insufficiency\n    3. Patients with G6PD deficiency","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Failed Voiding Trial","description":"Number of participants with a failed postoperative voiding trial. A failed voiding trial is defined as not voiding all urine in 20 minutes or voiding less than 1/3 of total volume (voided volume + post void residual). Patients will undergo voiding trial at same day surgery per the following protocol. Participants who do not pass the voiding trial the same day of their surgical procedure return to the clinic in 3 days to repeat it, following the same protocol described above.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Pain From Pre to Post Procedure Using the Visual Analog Scale (VAS)","description":"To determine if the phenazopyridine has an analgesic effect after the retropubic midurethral slings, participants will be asked to self-report pain intensity preoperatively and then postoperatively (2 to 3 hours post procedure) using the Visual Analog Scale (VAS). The scale of the VAS is from 0 meaning \"no pain\" to 10 indicating the \"worst pain.\" The resulting change is measured as the difference between the self-reported preoperative pain score and the postoperative pain score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.31"},{"groupId":"OG001","value":"1.21","spread":"1.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":44},"commonTop":[]}}}